445-04-5

Usage

Uses

Used in Scientific Experiments:
4-Amino-3-(trifluoromethyl)phenol is used as a reagent for various scientific experiments, providing a unique structure that can be manipulated in chemical reactions.
Used in Chemical Reactions:
4-Amino-3-(trifluoromethyl)phenol is used as a reactant in chemical reactions, where its trifluoromethyl group and aminophenol structure contribute to the formation of new compounds.
Used in Synthesis of Complex Molecules:
4-Amino-3-(trifluoromethyl)phenol is used as a building block in the synthesis of more complex molecules, leveraging its unique properties to create advanced chemical structures.
Used in Pharmaceutical Industry:
4-Amino-3-(trifluoromethyl)phenol is used as a precursor in the development of pharmaceutical compounds, potentially leading to new drug candidates with novel therapeutic properties.
Used in Material Science:
4-Amino-3-(trifluoromethyl)phenol is used in the development of new materials, where its unique chemical structure can influence the properties of the resulting materials, such as their solubility, reactivity, or stability.

InChI:InChI=1/C7H6F3NO/c8-7(9,10)5-3-4(12)1-2-6(5)11/h1-3,12H,11H2

Upstream product

• 88-30-2 3-trifluoromethyl-4-nitrophenol 
• 98-17-9 3-Trifluoromethylphenol 
• 393-11-3 4-nitro-3-(trifluoromethyl)benzeneamine 
• 98-16-8 3-trifluoromethylaniline 
• 365-49-1 4-phenylazo-3-trifluoromethyl-phenol 

Downstream Products

• 346-29-2 4-acetamido-3-(trifluoromethyl)phenyl acetate 
• 393-40-8 2-(trifluoromethyl)cyclohexa-2,5-diene-1,4-dione 
• 884339-72-4 4-(4-amino-3-(trifluoromethyl)phenoxy)-3-nitropyridin-2-amine 
• 1352338-93-2 C₂₂H₁₈F₃N₅ 
• 1352342-58-5 C₂₂H₁₈F₃N₃OS 
• 1352338-92-1 C₂₂H₁₆F₄N₄O 
• 1352338-63-6 C₂₂H₁₇F₃N₄O 
• 1352337-43-9 C₂₂H₁₇F₃N₄O 
• 1352341-95-7 C₂₁H₁₈F₃NO₃ 
• 1352341-94-6 C₂₀H₁₆F₃NO₄ 

Relevant academic research and scientific papers

The aqueous photolysis of TFM and related trifluoromethylphenols. An alternate source of trifluoroacetic acid in the environment

The lampricide 3-trifluoromethyl-4-nitrophenol (TFM) is added annually to the Great Lakes (approximately 50 000 kg/y), with treatment concentrations varying from 1 to 14 mg/L at source. TFM was shown to undergo photohydrolytic degradation, at 365 nm and u

Novel achiral four-ring bent-shaped nematic liquid crystals with trifluoromethyl and methyl substituents in the central molecular core: An unusually large Kerr constant in blue phase III of nematic-chiral dopant mixture

Here, we report the first example of achiral bent-shaped liquid crystals comprising trifluoromethyl and methyl moieties on adjacent phenyl rings in the core, exhibiting nematic mesomorphism close to room temperature on cooling. The XRD confirms the existe

New clicked full agonists of the estrogen receptor β

A click chemistry approach was used to synthesize a series of 1,4-diaryl-substituted 1,2,3-triazoles designed to behave as estrogen receptor (ER) ligands. We studied their affinities for both receptors α and β, their agonist activities in a cell-based luciferase reporter assay and their effect on the proliferation of the hormone-dependent MCF-7 cell line. We found two compounds (3a and 3c) that behave as selective full agonists for ERβ at a 20 μM concentration, and one of them (3c) showed no proliferative effect on MCF-7 cells.

A scalable Nenitzescu synthesis of 2-methyl-4-(trifluoromethyl)-1H-indole- 5-carbonitrile

2-Methyl-4-(trifluoromethyl)-1H-indole-5-carbonitrile is a key intermediate in the synthesis of selective androgen receptor modulators discovered in these laboratories. A practical and convergent synthesis of the title compound starting from 4-nitro-3-(tr

Novel potent BRAF inhibitors: Toward 1 nM compounds through optimization of the central phenyl ring

BRAF, a serine/threonine specific protein kinase that is part of the MAPK pathway and acts as a downstream effector of RAS, is a potential therapeutic target in melanoma. We have developed a series of small-molecule BRAF inhibitors based on a 1H-imidazo[4,5-b]pyridine-2(3H)-one scaffold (ring A) as the hinge binding moiety and a number of substituted phenyl rings C that interact with the allosteric binding site. The introduction of various groups on the central phenyl ring B combined with appropriate A- and C-ring modifications afford very potent compounds that inhibit V600EBRAF kinase activity in vitro and oncogenic BRAF signaling in melanoma cells. Substitution on the central phenyl ring of a 3-fluoro, a naphthyl, or a 3-thiomethyl group improves activity to yield compounds with an IC50 of 1 nM for purified V 600EBRAF and nanomolar activity in cells.

Nonpeptide inhibitors of measles virus entry

Measles virus (MV) is one of the most infectious pathogens known. Despite the existence of a vaccine, over 500 000 deaths/year result from MV or associated complications. Anti-measles compounds could conceivably reverse these statistics. Previously, we described a homology model of the MV fusion protein trimer and a putative binding site near the head-neck region. The resulting model permitted the identification of two nonpeptidic entry inhibitors. Here, we present the design, synthesis, and bioevaluation of several series of fusion inhibitors and describe their structure-activity relationships (SAR). Five simply substituted anilides show low-μM blockade of the MV, one of which (AS-48) exhibits IC50 = 0.6-3.0 μM across a panel of wild-type MV strains found in the field. Molecular field topology analysis (MFTA), a 2D QSAR approach based on local molecular properties (atomic charges, hydrogen-bonding capacity and local lipophilicity), applied to the anilide series suggests structural modifications to improve potency.

Monocyclic heterocycles as kinase inhibitors

The present invention is directed to compounds having the formula and methods for using them for the treatment of cancer.

PROPIONAMIDE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS

Compounds of formula (I) wherein R1 to R4, X and A are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula (I) possess utility as tissue-selective androgen receptor modulators (SARM) and are useful in hormonal therapy, e.g. in the treatment or prevention of male hypogonadism and age-related conditions such as andropause.

Cyclohexylene-Bridged Porphyrin Quinones with Variable Acceptor Strength as Biomimetic Models for Photosynthesis: Evidence for Twist-Boat Conformation

Rigidly and covalently linked porphyrin quinones are well-suited as biomimetic model compounds for studying the photoinduced electron transfer (PET) reaction occurring in primary processes of photosynthesis. In this context, the synthesis of new porphyrin quinones with a cis- or trans-1,4-disubstituted cyclohexylene bridge linking the electron donor and the electron acceptor is reported. To study the dependence of the PET rate of the difference of the free enthalpy of the PET reaction, four quinones with different structures and therefore redox potentials were used as electron acceptor components. As a whole, two series of each four new cis- and trans-1,4-cyclohexylene-bridged porphyrin quinones with variable acceptor strength were synthesized. The most important synthetic steps comprised the free radical addition of the ester functionalized cyclohexylene bridge to the quinone, reduction of the ester to the alcohol group with lithium borohydride or DIBALH, oxidation of the alcohol to the corresponding aldehyde with PCC or TEMPO (2,2,6,6-tetramethylpiperidine1-oxyl)/NaOCl, and condensation of these aldehydes with pyrrole and 4-methylbenzaldehyde under equilibrium conditions. Analysis of the 1H NMR spectra unambiguously indicated the chair conformation for the cyclohexane ring of all porphyrin precursors and Zrarcs-cyclohexane-bridged porphyrin quinones, whereas the cis-cyclohexane-bridged porphyrin quinones had the cyclohexane ring in the unusual twist-boat conformation. This was additionally confirmed by an X-ray crystal structure of one of the cis-porphyrin quinones and the corresponding trans-porphyrin quinone. NOE experiments gave information about the spatial arrangement of the diastereomeric target compounds in solution.